Research progress in SELDI-TOF MS and its clinical applications

Chinese Journal of Biotechnology

Volumn 22, Issue 6, 2006, Pages 871-877

  CHO, William Chi Shing ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

proteinchip profiling; proteomics; surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI TOF MS); tumor biomarker

Indexed keywords

ANIMAL; ARTICLE; BIOLOGY; HUMAN; LASER; MASS SPECTROMETRY; METHODOLOGY; PROTEIN MICROARRAY; PROTEOMICS; SURFACE PROPERTY;

ANIMALS; COMPUTATIONAL BIOLOGY; HUMANS; LASERS; MASS SPECTROMETRY; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SURFACE PROPERTIES;

EID: 33845607725     PISSN: 18722075     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1872-2075(06)60061-7     Document Type: Article

References (50)

1. Hutchens T., and Yip T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Communications in Mass Spectrometry 7 (1993) 576-580
2. Cho W. Oncoproteomics and its research progress. Contemporary Academic Research 2 (2006) 8-12
3. Petricoin E., Ardekani A., Hitt B., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 9306 (2002) 572-577
4. Zhang Z., Bast Jr. R., Yu Y., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research 64 16 (2004) 5882-5890
5. Petricoin III E., Ornstein D., Paweletz C., et al. Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute 94 20 (2002) 1576-1578
6. Li J., Zhang Z., Rosenzweig J., et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry 48 8 (2002) 1296-1304
7. Xiao X., Liu D., Tang Y., et al. Development of proteomic patterns for detecting lung cancer. Disease Markers 19 1 (2003-2004) 33-39
8. Cho W., Yip T., Yip C., et al. Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clinical Cancer Research 10 1 (2004) 43-52
9. Cho WC, Yip TT, Ngan RK, et al. Proteinchip array profiling for identification of disease-and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clinical Chemistry, in press.
10. Lee I., Chen C., Sheu J., et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6 9 (2006) 2865-2873
11. Yu J., Chen Y., and Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World Journal of Gastroenterology 10 21 (2004) 3127-3131
12. Melle C., Ernst G., Schimmel B., et al. Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. International Journal of Oncology 28 1 (2006) 195-200
13. Vermeulen R., Lan Q., Zhang L., et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proceedings of the National Academy of Sciences of the United States of America 102 47 (2005) 17041-17046
14. Yip T., Chan J., Cho W., et al. Proteinchip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clinical Chemistry 51 1 (2005) 47-55
15. Austen B., Frears E., and Davies H. The use of SELDI proteinchip arrays to monitor production of Alzheimer's beta amyloid in transfected cells. Journal of Peptide Science 6 9 (2000) 459-469
16. Ruetschi U., Zetterberg H., Podust V., et al. Identification of CSF biomarkers for frontotemporal dementia using SELDITOF. Experimental Neurology 196 2 (2005) 273-281
17. de Seny D., Fillet M., Meuwis M., et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis and Rheumatism 52 12 (2005) 3801-3812
18. Cho W., Yip T., Chung W., et al. Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. Journal of Cellular Biochemistry 99 1 (2006) 256-268
19. Cho W., Yip T., Chung W., et al. Potential biomarkers found by proteomic profiling may provide insight for the macrovascular pathogenesis of diabetes mellitus. Disease Markers 22 3 (2006) 153-166
20. Cho W., Yip T., Chung W., et al. Altered expression of serum protein in ginsenoside Re treated diabetic rats detected by SELDI-TOF MS. Journal of Ethnopharmacology 108 2 (2006) 272-279
21. Jin M., Cataland S., Bissell M., et al. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. Journal of Thrombosis and Haemostasis 4 2 (2006) 333-338
22. Bouamrani A., Ternier J., Ratel D., et al. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clinical Chemistry 52 11 (2006) 2103-2106
23. Fung E., Thulasiraman V., Weinberger S., et al. Protein biochips for differential profiling. Current Opinion in Biotechnology 12 1 (2001) 65-69
24. Issaq H., Veenstra T., Conrads T., et al. The SELDITOF MS approach to proteomics: protein profiling and biomarker identification. Biochemical and Biophysical Research Communications 292 3 (2002) 587-592
25. Yanagisawa K., Shyr Y., Xu B., et al. Proteomic patterns of tumor subsets in nonsmallcell lung cancer. Lancet 362 9382 (2003) 433-439
26. Henderson N., and Steele R. SELDITOF proteomic analysis and cancer detection. Surgeon 3 6 (2005) 383-390 422
27. Wong D. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. Journal of the American Dental Association 137 3 (2006) 313-321
28. Annalisa C., Daniela C., Lau S., et al. Exploring the hidden human urinary proteome via ligand library beads. Journal of Proteome Research 4 6 (2005) 1917-1930
29. Chen E., Hewel J., Felding-Habermann B., et al. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Molecular and Cellular Proteomics 5 1 (2006) 53-56
30. Thulasiraman V., Lin S., Gheorghiu L., et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 26 18 (2005) 3561-3571
31. Cho W. Innovative trend of modern medicine-personalized medicine. Popular Medicine 10 (2004) 74-75
32. Cho W., Yue K., and Leung W. Proteomics-leading the post-genome era. Journal of Chinese Biotechnology 25 1 (2005) 33-38
33. Mueller J., von Eggeling F., Driesch D., et al. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. European Urology 47 6 (2005) 885-894
34. Mahnert B., Tauber S., Kriegmair M., et al. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer. Clinical Chemistry and Laboratory Medicine 41 1 (2003) 104-110
35. Li J., Zhang Z., Rosenzweig J., et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry 48 8 (2002) 1296-1304
36. Ciambellotti E., Coda C., and Lanza E. Determination++ of CA 15-3 in the control of primary and metastatic breast carcinoma. Minerva Medica 84 3 (1993) 107-112
37. Chen Y., Zheng S., Yu J., et al. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clinical Cancer Research 10 24 (2004) 8380-8385
38. Grotowski M., and Wojtun S. CEA, CA-19-9 and IL-8, sTNFRII and sIL-2R in persons at high risk of colorectal cancer. Polski Merkuriusz Lekarski 14 82 (2003) 327-330
39. Poon T., Sung J., Chow S., et al. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 130 6 (2006) 1858-1864
40. Lai I., Lee W., Huang M., et al. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 49 46 (2002) 1157-1160
41. Ward D., Cheng Y., N'Kontchou G., et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. British Journal of Cancer 94 2 (2006) 287-292
42. de Masi S., Tosti M., and Mele A. Screening for hepatocellular carcinoma. Digestive and Liver Disease 37 4 (2005) 260-268
43. Yang S., Xiao X., Zhang W., et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5 (2005) 83
44. Li R., Li R., and Wang Y. Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer. Chinese Journal of Tuberculosis and Respiratory Diseases 21 1 (1998) 26-29
45. Zhang Z., Bast Jr. R., Yu Y., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research 64 16 (2004) 5882-5890
46. Brazert J., Pietryga M., Szablonski W., et al. Diagnostic value of the morphological ultrasound score system and the serum concentration of CA 125 in the diagnosis of malignant ovarian cancer. Ginekologia Polska 74 12 (2003) 1542-1548
47. Koopmann J., Zhang Z., White N., et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clinical Cancer Research 10 3 (2004) 860-868
48. Yamaguchi K., Nagano M., Torada N., et al. Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas. Rinsho Byori 52 4 (2004) 336-339
49. Adam B., Qu Y., Davis J., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research 62 13 (2002) 3609-3614
50. Gann P., Hennekens C., and Stampfer M. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. Journal of the American Medical Association 273 4 (1995) 289-294